ARGOS
AGS
003-007 |
An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Learn more.
|
NCT01582672 |
Novartis
CRAD
101L2404
SLHN
2011-111 |
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
Learn more.
|
NCT01491672 |
SLHN
2011-113
Altor
BioScience |
A Phase Ib/II Trial of ALT-801 in Combination with Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Learn more.
|
NCT01326871 |
SLHN
2011-111
Novartis
CRAD001L2404 |
Open Label Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as a Second Line Therapy in the Treatment of Patients with Metastatic Renal Cell Carcinoma
Learn more.
|
NCT01491672 |